Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2024 | Hematopoiesis in ovarian cancer survivors to determine risk of secondary blood cancers

Elizabeth Swisher • 7 Apr 2024
AACR 2024
Gynecological Cancer Ovarian Cancer

Elizabeth Swisher, MD, University of Washington, Seattle, WA, discusses an ongoing study (NCT06295965) investigating clonal hematopoiesis in ovarian cancer survivors to determine risk of secondary blood cancers. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elizabeth Swisher

1:26
EDGE: increasing hereditary cancer screening rates in primary care
Elizabeth Swisher • 7 Apr 2024
0:49
Remotely delivered cancer genetic testing in the Making Genetic Testing Accessible (MAGENTA) trial
Elizabeth Swisher • 7 Apr 2024
0:35
Phase I dose expansion results of CYT-0851 plus capecitabine in platinum-resistant ovarian cancer
Elizabeth Swisher • 7 Apr 2024
1:51
BRCA and RAB: prognostic biomarkers in recurrent ovarian cancer
Elizabeth Swisher • 19 May 2020

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals